Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2Melanoma 1

Interventions

Specimen Handling 274Magnetic Resonance Spectroscopy 226pembrolizumab 225Carboplatin 178Biopsy 165Cisplatin 162Nivolumab 157Cyclophosphamide 146Paclitaxel 124Radiotherapy 123Gemcitabine 114Bevacizumab 92durvalumab 91Dexamethasone 87Rituximab 80Oxaliplatin 80venetoclax 73atezolizumab 70Doxorubicin 70Fluorouracil 69Docetaxel 69Capecitabine 68Etoposide 66Radiosurgery 65Ipilimumab 63Radiation 60Prednisone 60Cytarabine 60Lenalidomide 59fludarabine 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × famitinib × 90 days × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡